Do Tax Cuts Cause Inflation? Alex Brill on ‘The Price of Business’
On May 11, Alex Brill joined Kevin Price on his radio show, “The Price of Business,” to talk about whether tax cuts cause inflation. The short answer is: It depends.
‘The Price of Business’: Alex Brill Talks Rising Inflation
On April 21, Alex Brill made a special appearance on “The Price of Business” radio show to talk about the sharp rise of inflation and its effects on small businesses and individuals earning low wages.
Charitable Giving is Good. Be Smart About how to Encourage It.
In 2020, Americans’ individual charitable giving reached $324 billion, a record high and a 2.2 percent increase from 2019. While the pandemic imposed great costs on our society, many households shared their resources with others, including religious, educational, and human service organizations.
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition
MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
